Posters

One-year outcomes of intravitreal conbercept for polypoidal choroidal vasculopathy in a Chinese population

Poster Details

First Author: H.Qi CHINA

Co Author(s):    E. Jin                             

Abstract Details



Purpose:

This study aims to evaluate the outcomes of intravitreal injection of conbercept combined with thermal laser photocoagulation for treating polypoidal choroidal vasculopathy.

Setting:

A consecutive case series

Methods:

We reviewed treatment histories and outcomes of fifty-six polypoidal choroidal vasculopathy patients over twelve months in this study. Fifty-six eyes were treated initially with monthly intravitreal injection of 0.5 mg conbercept for three months and were followed-up monthly for a year. After the first three injections, the eyes that exhibited substantial polyp regression with improved visual acuity received additional intravitreal injections of conbercept. Eyes that exhibited partial or no polyp regression and poor visual acuity underwent rescue therapies: subfoveal polyps were treated with photodynamic therapy, and extrafoveal polyps were treated with thermal laser photocoagulation. Branching vascular networks were not treated.

Results:

The visual acuity of the 56 treated eyes improved significantly from 43.52 ± 24.21 letters at baseline to 52.72 ± 20.81 at month-three and 55.88 ± 21.94 letters at month-twelve(p < 0.001), with an increase of 13.25 ± 16.57 letters by the end of the study period. Central foveal thickness decreased significantly from 457.41 ± 207.86 mm at baseline to 252.32 ± 130.99 mm at month-three and 247.98 ± 127.08 mm at month-twelve(p < 0.001), with an average decrease of 209.43 ± 159.75 mm at the end of the study period. After the initial treatment with three injections of conbercept, 23 eyes (41.1%) exhibited complete polyp regression, 25 eyes (44.6%) exhibited partial polyp regression, and 8 eyes (14.3%) exhibited no change in polyps. At month-twelve, 44 eyes (78.6%) showed complete polyp regression. Out of these eyes, 27 eyes underwent conbercept monotherapy, with an average of 4.11 ± 1.58 injections; 17 eyes underwent combined rescue therapy, with 2 eyes undergoing photodynamic therapy and 15 eyes, laser photocoagulation. Twelve eyes (21.4%) exhibited partial polyp regression after an average of 5.42 ± 1.58 injections of conbercept; no rescue therapy was used. Overall, the patients received 4.30 ± 1.43 injections per eye.

Conclusions:

Conbercept is effective and safe in treating polypoidal choroidal vasculopathy in the Chinese population. A treatment regimen of three initial injections combined with subsequent additional injections or rescue therapies is efficacious and cost-effective.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy